Stemgent Completes Acquisition of Asterand’s Human Tissue Business

Purchase is step in building leading research tools business focused on human cells

Stemgent Completes Acquisition of Asterand's Human Tissue Business

RMG Associates, LLCRobert Gottlieb, 857-891-9091

Stemgent, Inc. announced today that it has completed the acquisition of Asterand Plc's Human Tissue Business for $9 million. Asterand provides a set of high quality, human-tissue based tools for drug and drug target discovery that is highly complementary to Stemgent's growing portfolio of innovative research products and services to advance cellular reprograming and stem cell research.

"The Asterand acquisition is an important step in our efforts to build a significant research tools business focused on human cells," said Ian Ratcliffe, President and CEO of Stemgent. "Asterand's offerings, supply chain, and customer base among pharmaceutical, biotechnology, and diagnostic companies, along with Stemgent's position in the academic research market and expertise developing stem cell research products present multiple opportunities for growth."

Asterand's human tissue business includes the XpressBANK™ biobank and related services and PhaseZERO™ human tissue-based drug discovery research services. The biobank contains several hundred thousand consented, well characterized human tissue specimens, linked to clinical information, across a range of therapeutic areas. The unit also provides custom services such as isolation of specific cell lines and primary cells, tissue microarrays; and biofluids including blood serum and plasma. The PhaseZERO platform capitalizes on the biobank and includes human gene expression profiling in diseased and non-diseased tissue; human protein expression profiling; and human tissue-based primary cell assays for metabolism and toxicity analysis.

The human tissue and services operations will continue under the Asterand name. The combined organizations will have 100 employees with operations in the US and UK. Stemgent plans to retain Asterand's operations in Detroit, MI, and in Royston, UK.

Stemgent, Inc. develops and markets proprietary tools and services to advance the application of human cells in biomedical research and drug discovery. The company works alongside some of the world's leading stem cell researchers in developing innovative technologies and services to support and simplify human cell reprogramming, growth, and differentiation. Product offerings include mRNA and viral reprogramming technologies, mRNA differentiation, small molecules, RNA and DNA transfection reagents, cytokines, antibodies, and cell culture media. The company's Asterand unit provides well characterized human tissue specimens through its XpressBioank™ and human tissue-based drug discovery services through its Phase ZERO™ platform. For more information, please visit and .

Suggested Articles

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.

A new and unproved COVID-19 cell therapy from a New Jersey biotech has been given a quick trial approval by the FDA.

The VC shop raised the money across two funds that will deploy cash to help biotechs get started and grow into more established players.